Treatment of progressive neurodegenerative disease with ibudilast

Abstract

Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).

What is claimed is: 
     
         1 . A method of treating a subject diagnosed with a myelopathy comprising administering to the subject a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least 3 months. 
     
     
         3 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least six months. 
     
     
         4 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least one year. 
     
     
         5 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least two years. 
     
     
         6 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily. 
     
     
         7 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least twice daily. 
     
     
         8 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least three times daily. 
     
     
         9 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally. 
     
     
         10 . The method of  claim 1  in which the ibudilast or pharmaceutically acceptable salt thereof is administered parenterally, enterally, intravenously, intranasally, or sublingually. 
     
     
         11 . The method of  claim 1 , in which the ibudilast or pharmaceutically acceptable salt thereof is administered through an injection. 
     
     
         12 . The method of  claim 1 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 0.1 mg to about 200 mg per day. 
     
     
         13 . The method of  claim 1 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 1 mg to about 240 mg per day. 
     
     
         14 . The method of  claim 1 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 30 mg to about 240 mg per day. 
     
     
         15 . The method of  claim 1 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 30 mg to about 180 mg per day. 
     
     
         16 . The method of  claim 1 , in which the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is selected from the group consisting of 30 mg/day, 60 mg/day, 90 mg/day, or 120 mg/day. 
     
     
         17 . The method of  claim 1 , in which the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is 60 mg/day. 
     
     
         18 . The method of  claim 1 , wherein the therapeutically effective amount is administered as a single dose or is divided into multiple dosages. 
     
     
         19 . The method of  claim 1 , wherein the therapeutically effective amount is administered in one, two, or three doses per day. 
     
     
         20 . The method of  claim 1 , wherein the ibudilast or a pharmaceutically acceptable salt thereof is administered as part of a combination therapy that includes one or more other therapeutic agents. 
     
     
         21 . The method of  claim 20 , wherein the one or more other therapeutic agents is approved and known to have a utility in the myelopathy. 
     
     
         22 . The method of  claim 1 , wherein the subject is a human subject. 
     
     
         23 . A method of treating a subject diagnosed with a myelopathy comprising administering to the subject a therapeutically effective amount of ibudilast.